---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-124538"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T19:52:46.175539+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Delcath issues 2025 revenue guidance of $94-98M, plans to enter Medicaid drug rebate agreement

## Summary
- Revenue guidance $94-98M, >150% YoY growth.
- Gross margin 83-85%; positive adjusted EBITDA and cash flow each quarter in 2025.
- Plans to enter NDRA with CMS, effective Q3 2025, expanding Medicaid/340B access.
- CEO expects HEPZATO treatment volume to increase at least 200% in 2025 vs 2024.

## SEC filing metadata
- accession: 0001193125-25-124538
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000119312525124538/0001193125-25-124538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000119312525124538/d946891d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-124538
- JSON: https://secwatch.observer/filing/0001193125-25-124538.json
- Plain text: https://secwatch.observer/filing/0001193125-25-124538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.